Veracyte (VCYT) has drawn attention after recent share price gains over the past month and the past 3 months, prompting a closer look at how its diagnostics business and current valuation might align with investor expectations.

At a share price of $51.29, Veracyte has seen short term momentum build, with a 30 day share price return of 23.59% feeding into a 1 year total shareholder return of 91.24% and a 3 year total shareholder return of 98.34%.

If Veracyte's run has you thinking about what else is moving in healthcare diagnostics, it could be a good moment to scan for other specialised opportunities through our focused list of 41 healthcare AI stocks.

With Veracyte stock now trading around $51 and sitting close to some analyst targets, the key question for investors is whether the recent surge still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 4.5% Overvalued

Veracyte's most followed valuation narrative puts fair value at $49.10, slightly below the recent $51.29 close. This frames the current rally as running ahead of that model.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Curious what kind of revenue path, margin shape, and earnings multiple are baked into that story, all discounted back at just over 7%? The full narrative lays out the growth runway, how profits are expected to track that expansion, and what sort of premium P/E the market would need to keep assigning Veracyte for the numbers to line up.

Result: Fair Value of $49.10 (OVERVALUED)

However, the Veracyte story can change quickly if reimbursement for Afirma or Decipher tightens, or if newer tests struggle to secure guideline support and payer coverage.

Another View: Veracyte Through The Cash Flow Lens

While the most followed Veracyte narrative points to a fair value of $49.10 and labels the stock as 4.5% overvalued, the Simply Wall St DCF model presents an estimated future cash flow value of $57.53, or about 11% above the current $51.29 price.

If cash flows matter more to you than earnings multiples, this gap suggests a different risk reward balance than the 4.5% overvaluation story. The question is which lens you trust more when thinking about what you are really paying for Veracyte today.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Veracyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals on Veracyte have you on the fence, it might be worth checking the underlying data now and deciding where you stand. To see what optimistic investors are focusing on, review the 3 key rewards.

Looking for more investment ideas beyond Veracyte?

If Veracyte has sharpened your focus on stock selection, do not stop here. Use the Simply Wall St screener to uncover fresh ideas that fit your style.

• Target potential bargains by scanning for companies that combine quality fundamentals with attractive pricing using the 45 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses that score well on financial strength with the 65 resilient stocks with low risk scores.
• Spot early opportunities by reviewing the screener containing 20 high quality undiscovered gems before they sit on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.